Dow Jones

40 211,72

0,53%

DAX

Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NYSE
Teva Pharmaceutical Industries Ltd (TEVA)
Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NYSE:TEVA

<< Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
01/12/2021	14h00	Business Wire	Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
25/11/2021	18h00	GlobeNewswire Inc.	Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
24/11/2021	13h51	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
10/11/2021	15h17	Business Wire	Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
09/11/2021	11h56	Business Wire	Von der Effektivität im Rahmen klinischer Versuchsreihen zur tatsächlichen Wirksamkeit - erste Daten zu AJOVY® ▼ (Fremanezumab) aus dem European Real World Evidence Programm	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
09/11/2021	11h54	Business Wire	De l'efficacité clinique à l'efficacité en monde réel : les premières données AJOVY® ▼ ▼ (frémanezumab) du programme European Real World Evidence	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
08/11/2021	22h02	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
08/11/2021	10h25	Business Wire	From Clinical Trial Efficacy to Real-World Effectiveness First AJOVY® ▼ (fremanezumab) Data from European Real World Evidence Program	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
04/11/2021	21h43	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
03/11/2021	11h00	Business Wire	Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and Access to Medicine Targets	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
02/11/2021	22h31	Business Wire	Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
02/11/2021	22h30	Edgar (US Regulatory)	Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
02/11/2021	03h00	Business Wire	California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About Opioids	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
30/10/2021	22h00	Business Wire	New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
27/10/2021	14h52	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
27/10/2021	13h15	Business Wire	Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
27/10/2021	13h15	Business Wire	Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
27/10/2021	13h14	Edgar (US Regulatory)	Quarterly Report (10-q)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
27/10/2021	13h00	Business Wire	Teva Reports Third Quarter 2021 Financial Results	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
26/10/2021	22h45	Business Wire	Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
21/10/2021	14h00	Business Wire	Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
13/10/2021	19h53	Business Wire	Nouvelles données relatives à l'innocuité du traitement par COPAXONE® (acétate de glatiramère) chez des mères allaitantes atteintes de sclérose en plaques cyclique	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
13/10/2021	17h33	Business Wire	Neue Sicherheitsdaten zur Behandlung mit COPAXONE® (Glatirameracetat) von stillenden Müttern mit schubförmiger multipler Sklerose	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
13/10/2021	08h00	Business Wire	New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
04/10/2021	19h59	Business Wire	Les distances parcourues par les médicaments deviennent une source d'inquiétude pour les patients européens	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
04/10/2021	16h54	Business Wire	„Medicine Miles“ werden zu einem Problem für europäische Patienten	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
04/10/2021	13h21	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
04/10/2021	08h00	Business Wire	‘Medicine Miles’ Becoming a Concern for European Patients	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
01/10/2021	16h20	Business Wire	Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021	NYSE:TEVA	Teva Pharmaceutical Industries Ltd
30/09/2021	14h00	Business Wire	Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCN	NYSE:TEVA	Teva Pharmaceutical Industries Ltd